ClinicalTrials.gg

Program

brexanolone

Also written as “SAGE-547”, “Brexanolone” and “LPCN 1154A”.

Its studies are mostly in Depression, Postpartum · Status Epilepticus · Tinnitus · Respiratory Distress Syndrome · Essential Tremor, led by 2 companies.

Furthest: phase 4, since Feb 14, 202014 company-led studies, 1 open or runningNext primary completion: Aug 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Supernus Pharmaceuticals120 open or runningphase 4since Feb 14, 2020Jan 28, 2014none ahead
Lipocine21 open or runningphase 3since May 13, 2025May 13, 2025Aug 2027phase 3 · NCT07822321

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 28, 2014First study: phase 2 study in Status EpilepticusNew to Supernus PharmaceuticalsSupernus Pharmaceuticals · NCT02052739 · 25 enrolled · United States
  2. Oct 22, 20142 phase 2 studiesSupernus Pharmaceuticals · NCT02285504, NCT02277106
  3. Jun 2, 2015Phase 3 study in Super-Refractory Status EpilepticusSupernus Pharmaceuticals · NCT02477618 · 132 enrolled · United States, Austria, Canada and more
  4. Nov 2, 2015Phase 2 study in Depression, PostpartumSupernus Pharmaceuticals · NCT02614547 · 21 enrolled · United States
  5. Oct 20, 20162 phase 3 studies in Depression, PostpartumSupernus Pharmaceuticals · NCT02942017, NCT02942004
  6. Apr 30, 2018Phase 3 study in Depression, PostpartumSupernus Pharmaceuticals · NCT03665038 · 28 enrolled · United States
  7. Feb 14, 2020Phase 4 study in Depression, PostpartumSupernus Pharmaceuticals · NCT04273191
  8. Sep 1, 2020Phase 3 study in Respiratory Distress SyndromeSupernus Pharmaceuticals · NCT04537806 · 29 enrolled · United States
  9. Sep 17, 2021Phase 4 study in Depression, PostpartumSupernus Pharmaceuticals · NCT05059600 · 52 enrolled · United States
  10. Dec 1, 2022Phase 2 study in TinnitusSupernus Pharmaceuticals · NCT05645432 · 10 enrolled · United States
  11. May 13, 2025Lipocine's first study: phase 3 study in Depression, PostpartumNew to LipocineLipocine · NCT06979544 · 90 enrolled · United States
  12. Sep 10, 2026Phase 3 study in Depression, PostpartumLipocine · NCT07822321 · 120 planned · United States

Ahead

  1. Aug 2027Primary completion: phase 3 study in Depression, PostpartumLipocine · NCT07822321

TargetBeta

“GABA-A receptor; anion channel positive allosteric modulator”ChEMBL 37, by rule

Other programs on the same 16 targets

ProgramCompanyFurthest phaseStudies
MidazolamrulePfizerphase 496
ciprofolruleHaisco Pharmaceutical Groupphase 436
AlprazolamruleViatrisphase 435
DiazepamruleAcorda Therapeuticsphase 39

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07822321Depression, Postpartum · United States3RecruitingLipocineAug 2027120
NCT06979544Depression, Postpartum · United States3CompletedLipocineJan 16, 202690
NCT05645432Tinnitus · United States2CompletedSupernus PharmaceuticalsNov 21, 202310
NCT05059600Depression, Postpartum · United States4CompletedSupernus PharmaceuticalsJul 14, 202252
NCT04537806Respiratory Distress Syndrome · United States3TerminatedSupernus PharmaceuticalsJul 1, 202129
NCT04273191Depression, Postpartum4WithdrawnSupernus PharmaceuticalsAug 20210
NCT03665038Depression, Postpartum · United States3CompletedSupernus PharmaceuticalsJan 8, 202128
NCT02942017Depression, Postpartum · United States3CompletedSupernus PharmaceuticalsSep 17, 2017108
NCT02942004Depression, Postpartum · United States3CompletedSupernus PharmaceuticalsSep 24, 2017138
NCT02614547Depression, Postpartum · United States2CompletedSupernus PharmaceuticalsJun 22, 201621
NCT02477618Super-Refractory Status Epilepticus · United States, Austria, Canada and more3CompletedSupernus PharmaceuticalsJul 18, 2017132
NCT02285504Depression, Postpartum · United States2CompletedSupernus PharmaceuticalsJun 5, 20154
NCT02277106Essential Tremor · United States2CompletedSupernus PharmaceuticalsAug 14, 201525
NCT02052739Status Epilepticus · United States2CompletedSupernus PharmaceuticalsMay 3, 201525

How it is read

Names in the registry

  • “SAGE-547”, 5 entries
  • “Brexanolone”, 4 entries
  • “LPCN 1154A”, 2 entries
  • “SAGE-547 90 μg/kg/h”, 2 entries
  • “SAGE-547 60 μg/kg/h”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.